Evidence map›Paper›PMID 39511522›Full record

ArticleBMC psychiatry2024

Olanzapine for young PEople with aNorexia nervosa (OPEN): results of a feasibility study.

Olena Said, Dominic Stringer, Ece Sengun Filiz, Hiba Mutwalli, Sevgi Bektas, Melahat Nur Akkese, Vanessa Kellermann, Katie Ireland, Elizabeth Tyrrell-Bunge, Demelza Beishon-Murley and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Olena SaidCentre for Research in Eating and Weight Disorders (CREW), Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AD, UK.
Dominic StringerKing's Clinical Trials Unit, King's College London, London, UK.
Ece Sengun FilizDivision of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.
Hiba MutwalliCentre for Research in Eating and Weight Disorders (CREW), Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AD, UK.
Sevgi BektasCentre for Research in Eating and Weight Disorders (CREW), Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AD, UK.
Melahat Nur AkkeseCentre for Research in Eating and Weight Disorders (CREW), Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AD, UK.
Vanessa KellermannDepartment of Health Service and Population Research, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Katie IrelandSouth London and Maudsley NHS Foundation Trust, London, UK.
Elizabeth Tyrrell-BungeSouth London and Maudsley NHS Foundation Trust, London, UK.
Demelza Beishon-MurleySouth West London and St George's Mental Health NHS Trust, London, UK.
Joel W T KhorSouth West London and St George's Mental Health NHS Trust, London, UK.
Lee AllmanSussex Partnership NHS Foundation Trust, Hampshire, UK.
Joanna BarkerSolent NHS Trust, Southampton, United Kingdom.
Nicus KotzeDorset Healthcare University NHS Foundation Trust, Poole, Dorset, UK.
Ben CarterKing's Clinical Trials Unit, King's College London, London, UK.
Mima SimicSouth London and Maudsley NHS Foundation Trust, London, UK.
Dilveer Singh SuallyCentre for Research in Eating and Weight Disorders (CREW), Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AD, UK.
Jessica BentleyCentre for Research in Eating and Weight Disorders (CREW), Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AD, UK.
Allan H YoungCentre for Research in Eating and Weight Disorders (CREW), Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AD, UK.
Sloane MaddenUniversity of Sydney, Sydney, Australia.
Sarah ByfordDepartment of Health Service and Population Research, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Sabine LandauKing's Clinical Trials Unit, King's College London, London, UK.
Vanessa LawrenceDepartment of Health Service and Population Research, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Janet TreasureCentre for Research in Eating and Weight Disorders (CREW), Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AD, UK.
Ulrike SchmidtCentre for Research in Eating and Weight Disorders (CREW), Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AD, UK.
Dasha NichollsDivision of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.
Hubertus HimmerichCentre for Research in Eating and Weight Disorders (CREW), Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AD, UK. hubertus.himmerich@kcl.ac.uk.

Funding

National Institute for Health and Care Research NIHR130780
6 · The paper itself

Abstract

backgroundDespite the availability of evidence-based treatments for anorexia nervosa (AN), remission rates are moderate, and mortality is high. Olanzapine is used as adjunct therapy for AN in case of insufficient response to first-line treatments, even though the evidence is limited. Its effect on eating disorder (ED) psychopathology, its efficacy and tolerability, and its acceptability and adherence rate are unclear.

methodsWe assessed the feasibility of a future definitive trial on olanzapine in young people with AN in an open-label, one-armed feasibility study that aimed to include 55 patients with AN or atypical AN aged 12-24 who gained < 2 kg within at least one month of treatment as usual (TAU) during outpatient, inpatient, or day-care treatment. Time points for assessments were at baseline, 8 weeks, 16 weeks, and 6 or 12 months. We estimated the following planning parameters: Recruitment rate (number of patients who agreed to take olanzapine/number eligible), adherence rate (number adhering to treatment/number recruited) and attrition rate (number completing study assessments/number recruited). In addition, two exploratory effect size parameters were estimated: Mean change in body mass index (BMI) and mean change in ED psychopathology.

resultsFifty-two people were pre-screened (June 2022 to May 2023; 10 study sites in England). 13 were ineligible at pre-screening . Of the 39  approached, 4 were found ineligible at screening. Of the remaining 35 eligible, 10 declined and 5 did not take part for other reasons. Thus, 20 participants were recruited and started olanzapine (recruitment rate: 20/35 = 57%). 15 out of 20 (75%) continued olanzapine for ≥ 16 weeks, and 13 participants (65%) remained in the trial until follow-up (either 6 or 12 months). Participants experienced, on average, a decrease over time in their Eating Disorder Examination Questionnaire (EDE-Q) Global scores (0.07 per week, N = 20) and an increase in BMI (0.08 kg/m

conclusionsPossible reasons for the recruitment difficulties and low adherence rate include the high clinical workload of ED services during the COVID-19 pandemic and the reluctance of patients to agree to take olanzapine under the relatively restricted conditions of a clinical study.

trial registrationInternational standard randomised controlled trial register number: ISRCTN80075010. Registration date: 27/04/2022.

Indexed as

Anorexia NervosaAntipsychotic AgentsFeasibility StudiesOlanzapineAdolescentBody Mass IndexChildFemaleHumansMaleTreatment OutcomeYoung AdultAntipsychotic AgentsOlanzapineAdherenceAnorexia nervosaAttritionFeasibilityOlanzapineRecruitmentSide effects

Identifiers

PMID39511522
PMCPMC11542358

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.